The impact of introducing malaria rapid diagnostic tests on fever case management:A synthesis of ten studies from the ACT Consortium by Bruxvoort, Katia J et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
The impact of introducing malaria rapid diagnostic tests on fever case management
Bruxvoort, Katia J; Leurent, Baptiste; Chandler, Clare I R; Ansah, Evelyn K; Baiden, Frank;
Björkman, Anders; Burchett, Helen E D; Clarke, Siân E; Cundill, Bonnie; DiLiberto, Debora D;
Elfving, Kristina; Goodman, Catherine; Hansen, Kristian S; Kachur, S Patrick; Lal, Sham;
Lalloo, David G; Leslie, Toby; Magnussen, Pascal; Mangham-Jefferies, Lindsay; Mårtensson,
Andreas; Mayan, Ismail; Mbonye, Anthony K; Msellem, Mwinyi I; Onwujekwe, Obinna E;
Owusu-Agyei, Seth; Rowland, Mark W; Shakely, Delér; Staedke, Sarah G; Vestergaard,
Lasse S; Webster, Jayne; Whitty, Christopher J M; Wiseman, Virginia L; Yeung, Shunmay;
Schellenberg, David; Hopkins, Heidi
Published in:
American Journal of Tropical Medicine and Hygiene
DOI:
10.4269/ajtmh.16-0955
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Bruxvoort, K. J., Leurent, B., Chandler, C. I. R., Ansah, E. K., Baiden, F., Björkman, A., ... Hopkins, H. (2017).
The impact of introducing malaria rapid diagnostic tests on fever case management: A synthesis of ten studies
from the ACT Consortium. American Journal of Tropical Medicine and Hygiene, 97(4), 1170-1179.
https://doi.org/10.4269/ajtmh.16-0955
Download date: 03. Feb. 2020
Am. J. Trop. Med. Hyg., 97(4), 2017, pp. 1170–1179
doi:10.4269/ajtmh.16-0955
Copyright © 2017 by The American Society of Tropical Medicine and Hygiene
The Impact of Introducing Malaria Rapid Diagnostic Tests on Fever Case Management:
A Synthesis of Ten Studies from the ACT Consortium
Katia J. Bruxvoort,1* Baptiste Leurent,1 Clare I. R. Chandler,1 Evelyn K. Ansah,2 Frank Baiden,3 Anders Bjo¨rkman,4
Helen E. D. Burchett,1 Siaˆn E. Clarke,1 Bonnie Cundill,5 Debora D. DiLiberto,1 Kristina Elfving,6 Catherine Goodman,1
Kristian S. Hansen,1,7 S. Patrick Kachur,8 Sham Lal,1 David G. Lalloo,9 Toby Leslie,1 Pascal Magnussen,10,11
Lindsay Mangham-Jefferies,1 Andreas Ma˚rtensson,12 Ismail Mayan,13 Anthony K. Mbonye,14,15 Mwinyi I. Msellem,16
Obinna E. Onwujekwe,17 Seth Owusu-Agyei,18 Mark W. Rowland,1 Dele´r Shakely,4,19,20 Sarah G. Staedke,1
Lasse S. Vestergaard,10,21 Jayne Webster,1 Christopher J. M. Whitty,1 Virginia L. Wiseman,1,22 Shunmay Yeung,1
David Schellenberg,1 and Heidi Hopkins1
1London School of Hygiene & Tropical Medicine, London, United Kingdom; 2Ghana Health Service, Accra, Ghana; 3Ensign College of Public
Health, Kpong, Ghana; 4Karolinska Institutet, Stockholm, Sweden; 5Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United
Kingdom; 6University of Gothenburg, Gothenburg, Sweden; 7University of Copenhagen, Copenhagen, Denmark; 8USCenters for DiseaseControl
andPrevention,Atlanta,Georgia; 9LiverpoolSchool of TropicalMedicine, Liverpool,UnitedKingdom; 10Centre forMedical Parasitology,University
of Copenhagen and Copenhagen University Hospital, Copenhagen, Denmark; 11Department for Veterinary and Animal Sciences, University of
Copenhagen, Copenhagen, Denmark; 12Uppsala University, Uppsala, Sweden; 13Health Protection Research Organisation, Kabul, Afghanistan;
14Ministry of Health, Kampala, Uganda; 15Makerere University School of Public Health, Kampala, Uganda; 16Zanzibar Malaria Elimination
Programme, Tanzania; 17Department of Pharmacology and Therapeutics, University of Nigeria, Enugu, Nigeria; 18Kintampo Health Research
Centre, Kintampo, Ghana; 19Centre for Malaria Research, Karolinska Institutet, Stockholm, Sweden; 20Health Metrics at Sahlgrenska Academy,
University of Gothenburg, Gothenburg, Sweden; 21Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut,
Copenhagen, Denmark; 22School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia
Abstract. Since 2010, theWorld Health Organization has been recommending that all suspected cases of malaria
be conﬁrmedwith parasite-baseddiagnosis before treatment. These guidelines represent a paradigmshift away from
presumptive antimalarial treatment of fever. Malaria rapid diagnostic tests (mRDTs) are central to implementing this
policy, intended to target artemisinin-based combination therapies (ACT) to patients with conﬁrmed malaria and to
improvemanagement of patients with nonmalarial fevers. The ACTConsortium conducted ten linked studies, eight in
sub-Saharan Africa and two in Afghanistan, to evaluate the impact of mRDT introduction on case management
across settings that vary in malaria endemicity and healthcare provider type. This synthesis includes 562,368 out-
patient encounters (study size range 2,400–432,513). mRDTs were associated with signiﬁcantly lower ACT pre-
scription (range 8–69% versus 20–100%). Prescribing did not always adhere to malaria test results; in several
settings, ACTs were prescribed to more than 30% of test-negative patients or to fewer than 80% of test-positive
patients. Either an antimalarial or an antibiotic was prescribed for more than 75% of patients across most settings;
lower antimalarial prescription for malaria test-negative patients was partly offset by higher antibiotic prescription.
Symptomatic management with antipyretics alone was prescribed for fewer than 25% of patients across all sce-
narios. In community health worker and private retailer settings, mRDTs increased referral of patients to other
providers. This synthesis provides an overviewof shifts in casemanagement thatmay be expectedwithmRDT introduction
and highlights areas of focus to improve design and implementation of future case management programs.
INTRODUCTION
Providing appropriate antimalarial treatment to patients
who have malaria has been a long-standing challenge in fever
casemanagement and has traditionally relied on presumptive
symptom-based diagnosis. Many people with malaria do not
receive effective antimalarial medications, increasing their risk
of severe disease or death. At the same time, many of those
who receive antimalarials do not have malaria and are suffer-
ing from a nonmalaria illness which may need alternative
treatment.1 To improve the rational use of artemisinin-based
combination therapies (ACTs), the World Health Organization
(WHO) recommended in 2010 that all suspected cases of
malaria should have parasitological conﬁrmation before
treatment.2,3 These changes represent a paradigm shift from
presumptive antimalarial treatment of fever to targeted use of
ACTs only for those with a positive malaria test.
Central to implementing this policy change aremalaria rapid
diagnostic tests (mRDTs), relatively simple, inexpensive, and
reliable point-of-care tests that can be used where high-
quality microscopy services are not available.4 mRDTs are
intended to improve themanagement of suspectedmalaria
cases, increasing the use of ﬁrst-line antimalarials in pa-
tients with conﬁrmed malaria and encouraging the di-
agnosis and appropriate treatment of patients without
malaria.1 After the WHO policy change, mRDT pro-
curement surged from 45 million tests globally in 2008 to
314 million in 2014.5 Parasite-based diagnosis before
treatment is now a policy in public health facilities in most
malaria-endemic countries, and mRDTs are also being in-
troduced among private retail and community health
providers.6–14
Clinical trials and early pilot projects before the widespread
adoption of mRDTs supported their use, though with some
heterogeneity of results.15 Compared with presumptive
treatment with antimalarials, case management based on
mRDTs generally reduced antimalarial prescription, particu-
larly in settings with relatively high provider adherence to test
results and low malaria prevalence.16–22 On the other hand,
although provider adherence to negative mRDT results was
high in some studies,16,17,23,24 it was low in others.25–27
Comparable data from good-quality studies in a variety of
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contexts are needed to anticipate the effects of mRDT
implementation as these tests are rolled out at scale.
The ACT Consortium is a research partnership created to
address key questions and inform policy on ACT delivery.28
The Consortium conducted studies in 10 countries in Africa
and Asia, including 10 studies speciﬁcally designed to ad-
dress questions on improving the targeting of ACTs through
the use of mRDTs. These studies looked at the impact of
mRDT introduction on fever casemanagement across a range
of clinical and epidemiological contexts and among various
types of healthcare providers. Studies evaluated different
mRDT intervention packages, leading to heterogeneity that
precludes formal meta-analysis. The current synthesis com-
pares individual study results to identify patterns across
contexts and provide an overview of what may be expected
from mRDT implementation programs.
METHODS
Studies included in the analysis. ACT Consortium studies
were included in this analysis if they collected data on patient
consultations for suspectedmalaria, evaluatedan intervention
to implement mRDTs by healthcare providers, and included a
comparison group without the mRDT intervention. The 10
studies meeting these criteria are described in Table 1, in-
cluding the abbreviation for each study used throughout the
text. All studies received ethical approval from their host ac-
ademic institutions and national authorities; see open-access
publications for further details.29–38 Data are available at the
ACT Consortium data repository (https://actc.lshtm.ac.uk/) or
from the authors on request.
Eight studies took place in sub-Saharan Africa and two in
Afghanistan, in a mix of rural and urban settings. mRDTs
were introduced in health facilities only (Afgh1, Cam1,
Ghan1, Tanz1, Tanz2, and Uga1), among community health
workers (Afgh2 andUga2), in private drug shops only (Uga3),
or in a combination of public facilities, private pharmacies,
and drug shops (Nige1). Seven studies were cluster-
randomized trials of interventions to introduce mRDTs, two
studies were individually randomized trials (Afgh1 and
Ghan1), and one study was a descriptive “before and after”
evaluation (Tanz1). All patients that were eligible in each
study were included in the present analysis; typically, these
were patients with suspected malaria, although one study
included only children under age 5 years (Uga2), and two
studies collected data on all patient consultations (Tanz2
and Uga1). Data were collected using provider-completed
records of treatments administered (Afgh1, Afgh2, Ghan1,
Uga1, and Uga2), patient exit interviews (Tanz1), both of
these methods (Cam1, Nige1, and Tanz2), or provider-
completed recordswith follow-up interviews of a subsample
of patients (Uga3).
Fromeach study, “settings” and “scenarios”were identiﬁed
for this analysis. Six studies were conducted in multiple set-
tings (indicated by sufﬁx a, b, and c), such as distinct geo-
graphical areas and malaria transmission zones (Afgh1,
Afgh2, Cam1, Tanz1, and Uga2), or where providers used
different methods of routine malaria diagnosis (presumptive
care or microscopy; Afgh1 and Ghan1). Trial arms or com-
parison groups within a setting were termed scenarios. All
settings included at least one scenario without mRDT inter-
ventions, and settings in three studies (Cam1, Nige1, and
Tanz2) included multiple mRDT intervention scenarios. In to-
tal, the 10 studies were conducted in 18 settings, with 18
scenarios without mRDT interventions and 24 scenarios with
mRDT interventions.
Data were collected concurrently from scenarios with and
without mRDT interventions in seven studies. In three studies
(Nige1, Tanz1, and Tanz2), data from scenarios without mRDT
interventions were collected before mRDT introduction. The
scale of the interventions and their evaluations varied: for
example, inUga1 the interventionwas implemented in10health
facilities, and data were collected on 432,513 patient encoun-
ters in the study area whereas Tanz1 evaluated a nationwide
intervention, and data were collected from 3,456 patients.
Microscopy waswidely available in all settings in Cam1 and
available at some higher-level facilities in Tanz1, particularly in
the Tanz1/c scenario without mRDT interventions. The two
individually randomized studies (Afgh1 andGhan1) took place
both in settings where microscopy was the standard practice
and in settings where malaria diagnosis was symptom based.
Microscopy services were nonexistent or very limited in the
other six studies (Afgh2, Nige1, Tanz2, Uga1, Uga2, and
Uga3).
Indicators of interest. To examine the impact of mRDTs
on patient care, malaria testing and prescribing indicators
were reviewed. Because the objective was to compare case
management in areas with and without mRDT interventions,
the ﬁrst indicator of interest was the proportion of patients
tested by the provider with any parasite-based diagnostic test
(microscopy or mRDT). Prescribing indicators were the pro-
portions of patients prescribed one or more of the following
medicines: ACTs, non-ACT antimalarials, antibiotics (anti-
bacterials), antifungals, antihelminthics, and antipyretics. The
proportion of patients referred to another healthcare provider
was also reviewed.
The ACT indicator was adjusted to account for malaria ep-
idemiology and differences in ﬁrst-line antimalarial in two
cases: In Afghanistan, Plasmodium vivax was treated with
chloroquine and Plasmodium falciparum with ACT; in these
settings, the proportion of patients prescribed any antimala-
rial is reported instead of ACT. In Nige1, prescription of
sulfadoxine-pyrimethamine (SP) andACTsare reported for the
scenario without mRDT interventions, whereas only ACTs are
reported for the scenarios with mRDT interventions. This re-
ﬂects a change in treatment between the 2009 scenario
without mRDT interventions (when ACTs were recommended
but not yet widely used) and the 2011 scenarios with mRDT
interventions (when ACTs had largely replaced SP).
Analytical approach. Descriptive statistics on the indica-
tors of interest were calculated from each scenario. Estimates
for each indicator were made for scenarios without mRDT
interventions and those with mRDT interventions. Prescribing
indicatorswere further stratiﬁedby result of the diagnostic test
performed by the healthcare provider. Odds ratios and 95%
conﬁdence intervals for indicators of interest within each
setting were calculated using logistic regression with robust
standard errors to account for clustering by the primary unit of
sampling or randomization (see Supplemental Tables). Formal
meta-analysis was deemed inappropriate because of the
heterogeneity of interventions evaluated and study contexts.
However, to aid comparisons between scenarios with and
without mRDT interventions, the indicators of interest are
presented as graphic point estimates by study arm. The
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analysis was conducted in STATA 14 (STATA Corp LP, Col-
lege Station, TX). Factors which may explain variations in
mRDT use are examined with additional qualitative data
sources elsewhere.39
RESULTS
Proportion of patients tested. More patients were tested
in scenarios where mRDTs had been introduced (Figure 1
and Supplemental Tables 1 3). However, even with mRDTs
available, the percentage of patients tested variedwidely, with
50%or fewer patients tested in ﬁve settings (Nige1, Tanz1/a,
Tanz1/b, Tanz2, and Uga1), and nearly 100% in others
(Afgh2/a, Afgh2/b, Uga/2, Uga2/b, and Uga3). The largest
increases in proportion of patients tested were seen where
mRDTs were introduced outside of health facilities (Afgh2,
Uga2, and Uga3). Similar proportions of children and adults
were tested in most scenarios, but in Nige1, Tanz1/a, and
Uga1 test uptake was slightly higher for young children than
for older patients. The proportion of patients tested is not
TABLE 1
Description of studies included in the analysis
Study country (reference) Context Healthcare provider type Dates Design Setting*
Scenario
description†
Number of
patients
Number of
clusters‡
Afgh1Afghanistan (29) Urban
and rural
Public health
facilities
September
2009–September
2010
Individually
randomized trial
Afgh1/a C 2,005 12
R1 2,048 12,
same
as C
Afgh1/b C 517 5
R1 527 5, same
as C
Afgh1/c C 323 5
R1 329 5, same
as C
Afgh2Afghanistan (30) Urban
and rural
Community health
workers
October 2011–May
2012
Cluster-randomized
trial
Afgh2/a C 607 6
R1 733 6
Afgh2/b C 594 5
R1 466 5
Cam1 Cameroon (31) Urban
and rural
Public and mission
health facilities
October–December
2011
Cluster-randomized
trial
Cam1/a C 400 5
R1 699 8
R2 778 9
Cam1/b C 281 4
R1 932 10
R2 891 10
Ghan1 Ghana (32) Rural Public health facilities August
2007–December
2008
Individually
randomized trial
Ghan1/a C 1,907 1
R1 1,904 1, same
as C
Ghan1/b C 1,727 3
R1 1,725 3, same
as C
Nige1 Nigeria (33) Urban
and rural
Public health facilities
and private medicine
retailers
July–December 2009
(formative),
June–December
2011 (trial)
Formative study
followed by cluster-
randomized trial
Nige1 C 1,642 100
R1 1,588 41
R2 1,850 47
R3§ 1,508 41
Tanz1 Tanzania (34) Rural/
periurban
Public health
facilities
May–October 2010
(baseline), April–July
2012 (follow-up)
Descriptive before
and after evaluation
Tanz1/a C 689 39
R1 750 60
Tanz1/b C 559 56
R1 388 60
Tanz1/c C 498 44
R1 572 57
Tanz2 Tanzania (35) Rural Public health
facilities
September 2010–
January 2011
(baseline), February
2011–Mar. 2012 (trial)
Baseline, followed by
cluster-randomized
trial
Tanz2 C 16,068 36
R1 14,217 12
R2 15,931 12
R3jj 13,973 12
Uga1 Uganda (36) Rural Public health facilities April 2011–March
2013
Cluster-randomized
trial
Uga1 C 210,758 10
R1 221,755 10
Uga2 Uganda (37) Rural Community health
workers
January–December
2011
Cluster-randomized
trial
Uga2/a C 2,444 32
R1 1,207 32
Uga2/b C 10,625 31
R1 7,872 30
Uga3 Uganda (38) Rural Private medicine
retailers
January–December
2011
Cluster-randomized
trial
Uga3 C 8,109 10
R2 10,365 10
Further details of the studies are available from individual study publications.
* Some studies had multiple “settings,” deﬁned as distinct geographical areas, malaria transmission zones, or different standard practices of malaria diagnosis. Where the study had only one
setting, the study and setting abbreviations are the same.
†C = Without malaria rapid diagnostic test (mRDT) interventions; R1 = mRDT intervention with basic provider training; R2 = mRDT intervention with enhanced provider training; R3 = mRDT
intervention with enhanced provider training and other activities.
‡Clusterswere health facilities in all studies, exceptNige1 (health facilities andprivatemedicine retailers), Uga2 (villages) andUga3 (drug shopswithin a single administrative area, anddrug shops
in a neighboring administrative area if the distance between drug shops was < 1 km).
§ The R3 intervention in Nige1 also included school-based activities.
jjThe R3 intervention in Tanz2 also included patient sensitization.
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reported in Afgh1 or Ghan1, where patients were indi-
vidually randomized to mRDTs or microscopy (Afgh1/a,
Afg1/b, and Ghan1/a), and to mRDTs or symptom-based
diagnosis (Afgh1/c and Ghan1/b).
Patientswere also testedwithmicroscopy inCam1and, to a
lesser extent, in Tanz1. In Cam1/a and Cam1/b, microscopy
was common in all scenarios, and test use was not higher in
scenarios with mRDT interventions. In scenarios without
mRDT interventions, 80% of patients were tested with mi-
croscopy. In the four scenarios with mRDT interventions,
27–61%of patientswere testedwithmicroscopyand17–52%
with mRDT (71–81% tested overall). Of the three Tanz1 set-
tings, microscopy was most frequently used in the Tanz1/c
scenario without mRDT interventions, where 29% of patients
were tested with microscopy and 2% with mRDT; in the cor-
responding scenario with mRDT interventions, 8% were
tested with microscopy and 63% with mRDT.
Prescription ofACTsand other antimalarialmedications.
Overall, mRDTs were associated with lower ACT prescribing
(Figure2AandSupplemental Table 4). In 10/13African settings,
mRDT scenarios had statistically signiﬁcantly lower ACT pre-
scriptions than scenarios without mRDT interventions. In two
African settings, there was little difference between mRDT and
non-mRDT scenarios: Uga1, a high-transmission area where a
highproportionofpatients requiredACTsevenafter testingand
Ghan1/a, where all non-mRDT patients were randomized to
testing with microscopy. In Nige1, where levels of testing were
very low, presumptive diagnosis of malaria was common even
where mRDTs were available. Prescription of ACT or SP in
the scenario without mRDT interventions was similar to
prescription of ACT in the three mRDT intervention scenarios
(around 50%). In 4/5 Afghanistan settings, prescription of
any antimalarial was much lower in scenarios with mRDT
interventions than without; the exception was Afgh1/b,
where (similar to Ghan1/a) all non-mRDT patients were ran-
domized to testing with microscopy and where malaria
transmission was low.
Recorded prescription of non-ACT antimalarials (e.g., SP,
quinine, oral, and artemisinin monotherapies) was generally
uncommon, except in Afghanistan. In 11/13 African settings,
non-ACTs were prescribed for fewer than 10% of patients
both with and without mRDT interventions (data not shown).
Prescription of non-ACT antimalarials was higher in Cam1/b
(20.9% in the scenario without an mRDT intervention and
approximately 15% in the two scenarios with mRDT inter-
ventions) and in Nige1 (52.8% in the scenario without an
mRDT intervention and approximately 30% in the three sce-
narios with mRDT interventions).
Overall, the ﬁnding of lower ACT prescription in scenarios
with mRDT interventions was mostly due to malaria test-
negative patients not receiving ACTs (Figure 2B–D and Sup-
plemental Table 5). Fewer than 30% of test-negative patients
were treated with ACTs in most mRDT intervention scenarios;
exceptions were Cam1/a and Cam1/b, and Ghan1/a and
Ghan1/b, where ACTs were prescribed for 39.2–49.1% of
patients with negative malaria test results. There was no evi-
dent difference in this indicator by test type; in theCam1/a and
Cam1/b scenarios with mRDT interventions, ACTs were pre-
scribed to 17.3–42.9% of microscopy test-negative patients
and 15.6–45.9% of mRDT test-negative patients (data not
shown). The percentages of malaria test-positive patients in
scenarios with mRDT interventions who were prescribed
ACTs ranged from60.2% to 98.0% in 12/15 settingswith data
for this indicator. Prescription of ACTs to test-positive patients
was over 90% in six of these settings, but was just 60.2–81.2%
in another six settings, with 69.4–96.2% prescribed any
antimalarial. In Tanz1/a, where stock-outs of ACTs in public
health facilities were a major problem, ACT prescribing for
test-positive patients was 18.2%. In Afgh1/a and Afgh2/a,
99.5% and 82.7% of test-positive patients were prescribed
any antimalarial.
Prescription of antibiotics. In contrast to reduced ACT
prescribing, the mRDT interventions were associated with
signiﬁcantly more prescribing of systemic antibiotic (anti-
bacterial) medications in seven settings (Afgh1/c, Afgh2/a,
Tanz1/a, Tanz1/b, Tanz1/c, Tanz2, and Uga3) (Figure 3 and
Supplemental Tables 6 7). In scenarios with mRDT interven-
tions, antibiotic prescribing patterns varied bymRDT result. In
all settings except Nige1, 40.0–79.9% of patients who tested
negative for malaria were prescribed antibiotics. Antibiotic
prescription was similar in patients who were not tested.
Among those with a positive malaria test result, fewer than
45% were prescribed antibiotics, with higher proportions in
Cam1/a and Cam1/b. Prescription of both an antimalarial
and a systemic antibiotic (Figure 4A and Supplemental
Table 8) was relatively uncommon in all settings (< 25% of
patients, except in Cam1 and Afgh2/b) and was similar or
lower in scenarios with mRDT interventions. By contrast, the
prescription of either an antimalarial or an antibiotic medicine
was high in all settings (more than 68%, except in Tanz1/a)
and similar or lower in scenarios with mRDT interventions
(Figure 4B and Supplemental Table 9). Further details of an-
tibiotic prescribing in ACT Consortium studies are presented
elsewhere.40
Prescription of other medicines. Data were recorded on
prescription of other anti-infectives in some study settings.
Prescription of systemic antifungals (ﬂuconazole and griseo-
fulvin) was reported in ﬁve settings (Cam1/a, Cam1/b,Ghan1/a,
Ghan1/b, and Uga1); the proportion of patients prescribed
these medicines across these settings was 2.6% or less
(Supplemental Table 10). Prescription of antihelminthics
(albendazole and mebendazole) was recorded in 13 settings
(all study settings except those in Afgh2, Tanz2, and Uga2);
the proportion of patients prescribed these medicines ranged
from 0.3% to 33.3%, which did not appear attributable to
whether the scenarios had an mRDT intervention or not
(Supplemental Table 10).
Prescription of antipyretic medicines alone, for symptom-
atic relief, without an antimalarial or an antibiotic, ranged
from 0.3% to 23.7% across all scenarios and was similar or
higher with mRDT interventions except in Nige1 (Figure 4C
and Supplemental Table 11). Polypharmacy, deﬁned as the
prescription of three or more medicines, varied widely across
settings (Figure 4D).However, inmost settings, polypharmacy
was comparable with and without mRDT interventions, but
was signiﬁcantly lower with mRDT interventions in four set-
tings (Afgh1/b, Afgh2/a, Afgh2/b, and Cam2/b (Figure 4D and
Supplemental Table 12).
Referral. Figure 5 and Supplemental Table 13 show the
percentage of patients referred to another care provider or
facility. Referral was generally low across study settings.
However, referral was signiﬁcantly higher with mRDT inter-
ventions among community health workers, particularly in
Uga2/a, Uga2/b, and Afgh2/b, and to a lesser extent in Uga3.
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FIGURE 1. Patients in scenarios without and withmalaria rapid diagnostic test (mRDT) interventions that were tested with anymalaria diagnostic
test at the provider of (A) all patients, (B) patients under age ﬁve years, and (C) patients ages ﬁve years and older. Afgh1 and Ghan1 studies
individually randomized patients to malaria diagnostic method and are not included in this analysis. Some settings had more than one mRDT
intervention scenario,which are graphed separately using the color and symbol for the setting. These includeCam1/a andCam1/b (two intervention
scenarios each),Nige1 (three interventionscenarios), andTanz2 (three intervention scenarios). SeeTable1.Scenarioswithdenominators fewer than
50 patients in Figure 2B are Afgh2/a without mRDT interventions and Afgh2/b both with and without mRDT interventions.
FIGURE 2. Patients prescribed an artemisinin-based combination therapy (ACT) of all patients in scenarios without and with malaria rapid
diagnostic test (mRDT) interventions and by test result for all patients in scenarios with mRDT interventions. Graphs depict the percentage of
patients prescribed ACT except for: Afgh1 and Afgh2, where all antimalarials are included to account for Plasmodium vivax treatment; and Nige1
without mRDT interventions only, where ACT or sulfadoxine-pyrimethamine (SP) are included to reﬂect treatment practices at the time of data
collection. Scenarioswith denominators fewer than 10patients are not graphed, resulting in some points without adjoining lines: Afgh2/a and Afgh2/b
in the “Not tested” column and Afgh1/b, Afgh1/c, and Afgh2/b in the “Positive test result” column. Afgh1 and Ghan1 studies individually randomized
patients to malaria diagnostic method; data are not included in the “Not tested” column because all patients in mRDT intervention scenarios were
tested. Some settings had more than one mRDT intervention scenario, which are graphed separately using the color and symbol for the setting.
These includeCam1/aandCam1/b (two intervention scenarios each),Nige1 (three intervention scenarios), andTanz2 (three intervention scenarios).
See Table 1. The following scenarios with denominators fewer than 50 patients are included: Uga2 in the “Not tested” column, and Cam1/a (R1),
Tanz1/b, and Uga2/a in the “Positive test result” column. All other scenarios had larger denominators.
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Referral was uncommon (< 5%) across all scenarios in studies
in public health facilities.
DISCUSSION
Providing appropriate treatment to patients who present
with malaria-like symptoms remains a challenge in many en-
demic regions. This synthesis of data from 10 ACT Consor-
tium studies illustrates the impact of mRDTs on case
management. The data represent 24 scenarios where
mRDTs were introduced, compared with 18 scenarios
without mRDT interventions. This synthesis found that
mRDT interventions reduced prescription of ﬁrst-line anti-
malarials across almost all settings, except where the tests
were not often used. However, prescribing did not always
reﬂect test results: across a range of scenarios, ACTs were
prescribed for some mRDT-negative cases, and at least as
concerning, ACTs were not prescribed for all mRDT-
positive cases. The use of mRDTs also inﬂuenced other
treatment decisions, notably resulting in an increase of
antibiotic prescription especially for test-negative cases.
Referral of patients to other healthcare providers was low
FIGURE 3. Patients prescribed an antibacterial of all patients in scenarioswithout andwithmalaria rapid diagnostic test (mRDT) interventions and
by test result for all patients in scenarioswithmRDT interventions. Somesettingshadmore thanonemRDT interventionscenario,whicharegraphed
separately using thecolor andsymbol for thesetting.These includeCam1/aandCam1/b (two interventionscenarioseach),Nige1 (three intervention
scenarios), and Tanz2 (three intervention scenarios). See Table 1. Community healthworkers in Uga2were not permitted to prescribe antibacterials
medications, so this study is not included in ﬁgure 3. Afgh1 andGhan1 studies individually randomized patients tomalaria diagnosticmethod; data
are not included in the “Not tested” column because all patients in scenarios with mRDT interventions were tested. Scenarios with denominators
fewer than 10 patients are not graphed, resulting in somepointswithout adjoining lines: Afgh2/a andAfgh2/b in the “Not tested” column, andAfgh1/b,
Afgh1/c, andAfgh2/b in the “Positive test result” column. The following scenarioswith denominators fewer than 50patients are included: Cam1/a (R1)
and Tanz1/b in the “Positive test result” column. All other scenarios had larger denominators.
FIGURE 4. Patients in scenarios without and with malaria rapid diagnostic test (mRDT) interventions prescribed (A) an antimalarial and an
antibacterial, (B) an antimalarial or an antibacterial, (C) an antipyretic without an antimalarial or an antibacterial, and (D) three or more medicines.
Some settings had more than one mRDT intervention scenario, which are graphed separately using the color and symbol for the setting. These
include Cam1/a and Cam1/b (two intervention scenarios each); Nige1 (three intervention scenarios) and Tanz2 (three intervention scenarios). See
Table 1. Community health workers in Uga2 were not permitted to prescribe antibacterials medications, so this study is not included in ﬁgure 4.
Tanz2 did not record data on all medications prescribed, so this study is not included in (D).
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across nearly all settings, with a few speciﬁc exceptions
discussed below.
What lessons can be learned from this synthesis, to inform
expectations of programs that implement mRDTs at scale?
Although mRDTs generally improve malaria case manage-
ment, alone, they are not a panacea to solve the major chal-
lenge of effective fever management. Simply providing
mRDTs is insufﬁcient if health workers continue prescribing
antimalarials to test-negative patients27,41 or if alternative
treatments are not appropriate. The ACT Consortium studies
evaluated a range of tailored andpretested elements as part of
mRDT intervention strategies, such as enhanced provider
training or community awareness activities.42,43 Anecdotally,
interventionsdesignedwithmore intensive formative research
led to greater reductions in ACT prescription for test-negative
patients; but such prescribing remained inappropriately high
(10–49%).
Furthermore, in ﬁve of the eight African studies included in
this analysis, more than 20% of patients who tested positive
for malaria at the point of care were not prescribed ACTs.
Undertreatment of malaria in settings where mRDTs have
been implemented has been recognized in a small proportion
of cases (less than 5%), with few exceptions.44–46 However,
results of this synthesis suggest that undertreatmentmay be a
more common problem than previously recognized. The six
settings with high ACT prescription for test-positive patients
varied in terms of malaria epidemiology, geography, and
provider type; the same is true for the six settings with lower
ACT prescription for test-positive patients. To date, research
into the reasons for this phenomenon has been limited, al-
though ACT Consortium study results presented elsewhere
suggest that provider motivations, stability of ACT supplies
and preexisting antimalarial preferences account for some of
this underprescription.39 Missed or ineffective treatment of
malaria presents a risk to patients; a balance between re-
ducing unnecessary antimalarial use while ensuring ACTs
are provided to all malaria-positive cases needs to be in-
tegrated in future research, training, and implementation
programs.
This synthesis highlights the fact that effecting change in
one healthcare practice can have knock-on consequences for
other practices. In many ACT Consortium studies, mRDT
implementationwasassociatedwith ahigher level of antibiotic
prescription, particularly for malaria test-negative patients.40
The proportion of patients prescribed either an antimalarial or
an antibiotic was high, for more than 75% of cases across
most settings, and this was approximately similar in settings
with andwithoutmRDT interventions. This suggests that in the
absence of other diagnostic options, presumptive antimalarial
treatment may be exchanged for presumptive antibiotic
treatment when mRDTs are introduced. Many patients with
uncomplicated febrile illness are likely to improve with
symptomatic management only (e.g., antipyretic), as noted
in WHO case management guidelines47,48; this approach
was prescribed for just 0–24% of patients in ACT Consor-
tium studies. Inappropriate use of antimicrobials is of in-
creasing global concern because of rising resistance, which
can result in longer illnesses, higher mortality, and in-
creased treatment costs.49,50 A more comprehensive ap-
proach to casemanagement is needed, rather than focusing
on only a single diagnosis and medication (e.g., malaria
mRDTs and ACTs), if unintended consequences are to be
avoided.51
Our data support the observation that introducing mRDTs
may increase patient referral to other healthcare providers,
particularly among community health workers and private
retailers.10,52 In particular, when a malaria test is negative,
alternative diagnoses must be considered; the clinical skills
and diagnostic capacity to achieve this are limited among
providers with less formal training, so that, referral may be
necessary for adequate casemanagement. Overall, referral
remained infrequent in ACT Consortium studies. Even
when referral is recommended, patients are not always
inclined or able to follow the recommendation.53–55 If cur-
rent recommendations to scale up mRDTs in community
and private healthcare settings are implemented, to im-
prove referral practices in a way that is safe for individual
patients, and without unduly burdening other parts of the
healthcare system, the role of mRDTs will need to be better
integrated into local pathways of treatment seeking and
care provision.56–58
The observed shifts in case management practices have
cost implications for health systems and for patients. When
mRDTs lead to reductions inACTuse, there canbe substantial
savings in ACT costs. However, additional costs are incurred
for mRDT implementation: the tests themselves, alternative
treatments provided to mRDT-negative patients, additional
referrals, and the activities required for mRDT introduction,
such as training, supervision, communication campaigns, and
quality control. The overall cost impact in a given context will
depend on several parameters, including the relative cost of
ACTs and mRDTs, the amount of subsidy for each, the pro-
portion of patients tested, the proportion who test positive,
and provider adherence to test results. Analyses of the in-
cremental economic cost per fever case managed have been
published for four studies included in this synthesis. Where
FIGURE 5. Patients in scenarios without and with malaria rapid di-
agnostic test (mRDT) interventions that were referred to another care
provider or health facility. Ghan1, Tanz1, Tanz2, and Uga1 did not
record data on referral. Case management was performed by com-
munityhealthworkers inAfgh2andUga2, privatedrugstore retailers in
Uga3, and both public and private health facilities in Nige1. All other
studies were conducted in public health facilities.
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mRDTs were compared with microscopy (Afgh1, Ghan1, and
Cam1), mRDTs were cost saving or costs were similar in
Afghanistan,59 with an incremental provider cost per fever
case managed ranging from 0.20 to 1.11 USD in in Ghana60
and Cameroon61 (2011 USD). Where mRDTs were compared
with clinical diagnosis, the incremental provider cost per fever
case managed ranged from 0.24 to 10.9 USD across different
transmission levels and provider types in Afghanistan, Ghana,
and Uganda (2011 USD).59,60,62 These incremental costs
may be considered good value for money if they lead to
sufﬁcient improvements in health outcomes. A full con-
sideration of cost effectiveness would require costs from
both health sector and household perspectives, extrapo-
lation to ﬁnal health outcomes such as cost per death or
disability adjusted life year averted, and sensitivity analy-
ses to explore the impact of variation in prescribing and
referral practices. Ideally, a full analysis should also include
the impact of malaria testing on enhancing malaria sur-
veillance systems and resulting improvements in targeting
of malaria interventions.
Thepresent analysiswassubject to several limitations.Data
were collected concurrently from scenarios with and without
mRDT interventions in seven studies, whereas in the other
three (Nige1, Tanz1, and Tanz2) data were collected before
and after mRDT introduction (Table 1). In Nige1, the interval
between the two data collection points corresponded with a
shift in antimalarial use from SP to ACT; whereas ACT pre-
scription decreased, any antimalarial prescription remained
high (³ 75%). In addition, some indicators varied in availability
andprecise deﬁnition across studies (see footnotes to Figures
andSupplemental Tables). For example, in Uga2, prescription
of antibiotics and polypharmacy was not reported because
community health workers were only permitted to dispense
antimalarials and antipyretics. In Tanz1, data on medicines
prescribed were not available from scenarios without
mRDTs, so data on medicines dispensed were used for all
Tanz1 scenarios. In designing the ACT Consortium studies
and mRDT implementation packages, investigators sought
to accommodate varied and transitioning contexts while
still obtaining data that could be compared across studies.
This synthesis therefore did not aim to provide combined
estimates of the size of effect of the impact of mRDTs
(meta-analysis). Instead, comparison of ﬁndings from the
individual studies identiﬁed clear patterns across diverse
geographical, epidemiological, and health sector contexts,
indicating both robustness and generalizability of the
results.
In summary, evidence from ten ACT Consortium studies
demonstrates that mRDT introduction can reduce pre-
scription of ACTs. However, mRDTs are not an easy tech-
nological ﬁx. Critically, challenges exist in ensuring that all
patients who test positive for falciparum malaria are pre-
scribed ACT; anything less endangers individual patients
and the credibility of programs. It is also necessary to ensure
that patients who test negative receive appropriate man-
agement, which may or may not include other antimicro-
bials. ACT Consortium studies were conducted between
2007 and 2013, and since that time, mRDT implementation
programs continue to evolve. These combined results pro-
vide an overview of the generally positive shifts in case
management thatmay be expectedwithmRDT introduction,
andhighlight issues thatwarrant particular attention in future
work on point-of-care diagnosis and fever and malaria case
management.
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